• The technology described in this briefing is myCOPD. It helps people with chronic obstructive pulmonary disease (COPD) to manage their symptoms and reduce the number of healthcare visits they need. It also helps the healthcare professionals care for people with COPD.

  • The innovative aspect is that it allows for care (such as pulmonary rehabilitation) to be provided remotely, based on a person's self-assessed needs. It can also help people with COPD to manage their condition at home where services are limited because of COVID-19.

  • The intended place in therapy would be as part of self-management for people as an alternative to some routine healthcare visits such as pulmonary rehabilitation.

  • The main points from the evidence summarised in this briefing are from 2 randomised controlled trials and 1 observational study, covering a total of 167 people with COPD. They show that myCOPD is associated with reduced COPD symptom severity and improved inhaler technique.

  • Key uncertainties are that the quantity and quality of evidence for myCOPD is limited. None of the studies followed up participants for longer than 3 months, so there is no medium- or long-term evidence. All studies had relatively few participants (fewer than 100), and had limited power to detect statistical differences between treatment groups.

  • The cost of myCOPD is £40 per person (excluding VAT). The resource impact would be in addition to standard care. The estimated cost of an 8-week outpatient pulmonary rehabilitation programme ranges from £522 to £1,044 per person.